ArticleVaccines2014
Immune System Regulation in the Induction of Broadly Neutralizing HIV-1 Antibodies.
Article in Vaccines, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 31 citations in OpenAlex.
- Self-tolerance curtails the B cell repertoire to microbial epitopes.JCI insight · 2019Trial
- Autoreactivity and broad neutralization of antibodies against HIV-1 are governed by distinct mutations: Implications for vaccine design strategies.Frontiers in immunology · 2022Article
- Tracing Self-Reactive B Cells in Normal Mice.Journal of immunology (Baltimore, Md. : 1950) · 2020Article
- Conditional antibody expression to avoid central B cell deletion in humanized HIV-1 vaccine mouse models.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Targeted selection of HIV-specific antibody mutations by engineering B cell maturation.Science (New York, N.Y.) · 2019Article
- Minding the gap: The impact of B-cell tolerance on the microbial antibody repertoire.Immunological reviews · 2019Review
- The HIV-1 Envelope Glycoprotein C3/V4 Region Defines a Prevalent Neutralization Epitope following Immunization.Cell reports · 2019Article
- Cross-reactivity of HIV vaccine responses and the microbiome.Current opinion in HIV and AIDS · 2018Review
- Targeted Elimination of Immunodominant B Cells Drives the Germinal Center Reaction toward Subdominant Epitopes.Cell reports · 2017Article
- Role of germinal centers for the induction of broadly-reactive memory B cells.Current opinion in immunology · 2017Review
- BCR and Endosomal TLR Signals Synergize to Increase AID Expression and Establish Central B Cell Tolerance.Cell reports · 2017Article
- Polyvalent vaccine approaches to combat HIV-1 diversity.Immunological reviews · 2017Review
- Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies.Immunological reviews · 2017Review
- Humanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem.Advances in immunology · 2017Review
- Determinants of HIV-1 broadly neutralizing antibody induction.Nature medicine · 2016Observational
- HIV-1 Envelope Trimer Design and Immunization Strategies To Induce Broadly Neutralizing Antibodies.Trends in immunology · 2016Review
- The role of Fc receptors in HIV prevention and therapy.Immunological reviews · 2015Review
- Can immunological principles and cross-disciplinary science illuminate the path to vaccines for HIV and other global health challenges?Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2015Review
- Honing a harder-hitting hammerhead improves broadly neutralizing antibody breadth and potency.The Journal of clinical investigation · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
In this brief review, we discuss immune tolerance as a factor that determines the magnitude and quality of serum antibody responses to HIV-1 infection and vaccination in the context of recent work. We propose that many conserved, neutralizing epitopes of HIV-1 are weakly immunogenic because they mimic host antigens. In consequence, B cells that strongly bind these determinants are removed by the physiological process of immune tolerance. This structural mimicry may represent a significant impediment to designing protective HIV-1 vaccines, but we note that several vaccine strategies may be able to mitigate this evolutionary adaptation of HIV and other microbial pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.